Education
About Us
Working with TipRanks
Follow Us
Enovis (ENOV)
NYSE:ENOV
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.74Last Year’s EPS
0.5Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: -10.07%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Positive
The earnings call highlights significant revenue growth and successful integration of the Lima acquisition, with strong new product launches and improved EBITDA margins. However, challenges include a substantial goodwill impairment, increased interest expenses, and potential tariff impacts. The positive aspects, particularly the strong growth and synergy realization, outweigh the negatives.Company Guidance
During the fourth quarter of 2024, Innovus reported a 23% increase in sales, achieving a 7% growth on a constant currency comparable basis. The company successfully expanded its adjusted EBITDA margins by 210 basis points, reaching 20.1%, and delivered an adjusted gross margin of 60.1%, marking a 150 basis point increase from the previous year. Innovus' Recon business exhibited notable performance with a 59% reported global revenue growth, driven by a 10% increase on a comparable basis, highlighted by double-digit growth in the Hip and Extremities segments. The U.S. Recon sector grew by 7%, complemented by a 13% international growth. The integration of Lima exceeded expectations, contributing to the company's strong commercial and operational trajectory. Enovis also provided guidance for 2025, projecting revenues between $2.19 billion and $2.22 billion with constant currency organic growth of 6% to 6.5%. Adjusted EBITDA is anticipated to be in the range of $405 million to $415 million, with an adjusted earnings per share range of $3.10 to $3.25.Strong Revenue Growth
Fourth quarter sales of $561 million, up 23% versus the prior year and up 7% on a comparable constant currency basis. Recon business grew 10% with double-digit growth globally across main segments in Hip, Knee, and extremities.
Successful Integration and Synergies from Lima Acquisition
The first year of the Lima acquisition exceeded revenue and profit goals, with successful channel and organizational integrations. Expected to deliver $40 million plus in synergies over three years.
Improved EBITDA Margins
Fourth quarter adjusted EBITDA grew 38%, with a margin of 20.1%, up 210 basis points versus the same quarter last year.
New Product Launches and Expansion
Strong momentum with new product launches, including revision cones, knees, augmented systems, and key launches in hip implants and enabling technology.
---
ENOV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ENOV Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $42.10 | $40.00 | -4.99% |
| Nov 06, 2024 | $43.31 | $46.90 | +8.29% |
| Aug 07, 2024 | $41.98 | $40.57 | -3.36% |
| May 02, 2024 | $55.40 | $52.13 | -5.90% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Enovis (ENOV) report earnings?
Enovis (ENOV) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Enovis (ENOV) earnings time?
Enovis (ENOV) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ENOV EPS forecast?
ENOV EPS forecast for the fiscal quarter 2025 (Q1) is 0.74.
---